Patient groupa

Neonate

Infant

Toddler

Child

Adolescent

Rocuronium dose (mg/kg)

0.45
(n=4)

0.6
(n=7)

1.0
(n=4)

0.45
(n=9)

0.6
(n=6)

1.0
(n=5)

0.45
(n=16)

0.6
(n=15)

1.0
(n=14)

0.45
(n=13)

0.6
(n=20)

1.0
(n=16)

0.45
(n=17)

0.6
(n=16)

1.0
(n=13)

Reappearance of T3, n
   Mean
   SD
   Median
   Range


4
49.5
11.6
48.2
39.2–
62.6


6
55.7
32.3
50.4
20.2–
111.7


2
114.4
30.9
114.4
92.6–
136.3


8
46.4
23.1
49.1
13.5–
79.9


6
62.3
20.4
57.9
32.3–
87.8


3
116.5
34.2
103.3
90.8–
155.4


15
35.3
11.3
39.1
16.9–
59.4


14
41.8
11.6
41.5
18.9–
59.3


12
76.1
23.6
72.5
42.0–
128.2


12
23.6
5.2
21.3
17.5–
31.5


20
38.3
11.6
38.9
21.7–
65.9


14
53.5
16.1
53.1
31.2–
89.9


16
37.0
13.4
36.7
18.3–
65.7


16
41.8
15.2
41.7
16.3–
81.9


11
61.6
19.4
65.6
25.6–
93.8

Onset of NMB, n
   Mean
   SD
   Median
   Range

4
1.22
0.67
1.06
0.58–
2.17

7
1.10
0.67
1.15
0.32–
2.07

4
0.82
0.67
0.57
0.33–
1.82

9
0.69
0.35
0.53
0.35–
1.25

6
0.52
0.21
0.53
0.23–
0.82

5
0.41
0.19
0.32
0.23–
0.70

16
0.83
0.47
0.77
0.32–
1.92

15
0.67
0.30
0.65
0.27–
1.55

14
0.57
0.32
0.49
0.23–
1.52

13
0.89
0.42
0.83
0.40–
1.92

20
0.87
0.33
0.85
0.32–
1.70

16
0.67
0.21
0.69
0.38–
1.17

17
1.10
0.38
1.02
0.53–
1.67

16
1.08
0.47
1.06
0.18–
2.08

13
0.72
0.17
0.68
0.53–
1.17

Recovery to TOF 0.9, n
   Mean
   SD
   Median
   Range


2
134.0
59.5
134.0
91.9–
176.1


2
119.6
42.7
119.6
89.4–
149.8


1
180.8

180.8


3
108.6
4.7
109.6
103.5–
112.7


4
111.2
30.6
109.2
77.5–
148.8


1
255.6

255.6


9
65.1
31.3
56.8
28.2–
125.2


10
68.1
19.9
68.6
28.4–
96.6


7
148.8
22.2
150.7
104.6–
172.7


12
46.5
15.2
45.4
26.7–
82.5


13
71.0
29.0
68.9
33.4–
137.9


9
76.0
26.8
83.7
44.0–
120.2


10
63.5
32.0
58.6
26.2–
133.5


11
73.4
24.8
79.2
28.6–
123.9


7
97.7
34.4
107.9
47.8–
143.1

aNeonates: birth to <28 days, infants: 28 days to ≤3 months, toddlers: >3 months to ≤2 years, children: >2 years to ≤11 years, and adolescents: >11 to ≤17 years;
Table 2: Time (minutes) from end of administration of rocuronium to: reappearance of T3, onset of neuromuscular blockade (NMB) and recovery to train-of-four (TOF) 0.9 (per-protocol group).